FDA Softens 'Dear Doctor' Letter Guidance For Drugmakers
The U.S. Food and Drug Administration backed down Tuesday from its recommendation that drugmakers evaluate the impact of their letters alerting physicians to new safety information about a drug, after manufacturers...To view the full article, register now.
Already a subscriber? Click here to view full article